| Literature DB >> 29860824 |
Sofie Bosch, Sofia El Manouni El Hassani, James A Covington1, Alfian N Wicaksono1, Marije K Bomers, Marc A Benninga2, Chris J J Mulder, Nanne K H de Boer, Tim G J de Meij.
Abstract
Fecal volatile organic compounds (VOCs) are increasingly considered to be potential noninvasive, diagnostic biomarkers for various gastrointestinal diseases. Knowledge of the influence of sampling conditions on VOC outcomes is limited. We aimed to evaluate the effects of sampling conditions on fecal VOC profiles and to assess under which conditions an optimal diagnostic accuracy in the discrimination between pediatric inflammatory bowel disease (IBD) and controls could be obtained. Fecal samples from de novo treatment-naïve pediatric IBD patients and healthy controls (HC) were used to assess the effects of sampling conditions compared to the standard operating procedure (reference standard), defined as 500 mg of sample mass diluted with 10 mL tap water, using field asymmetric ion mobility spectrometry (FAIMS). A total of 17 IBD (15 CD (Crohn's disease) and 2 UC (ulcerative colitis)) and 25 HC were included. IBD and HC could be discriminated with high accuracy (accuracy = 0.93, AUC = 0.99, p < 0.0001). A smaller fecal sample mass resulted in a decreased diagnostic accuracy (300 mg accuracy = 0.77, AUC = 0.69, p = 0.02; 100 mg accuracy = 0.70, AUC = 0.74, p = 0.003). A loss of diagnostic accuracy was seen toward increased numbers of thaw-freeze cycles (one cycle, accuracy = 0.61, AUC = 0.80, p = 0.0004; two cycles, accuracy = 0.64, AUC = 0.56, p = 0.753; and three cycles, accuracy = 0.57, AUC = 0.50, p = 0.5101) and when samples were kept at room temperature for 180 min prior to analysis (accuracy = 0.60, AUC = 0.51, p = 0.46). Diagnostic accuracy of VOC profiles was not significantly influenced by storage duration differences of 20 months. The application of a 500 mg sample mass analyzed after one thaw-freeze cycle showed the best discriminative accuracy for the differentiation of IBD and HC. VOC profiles and diagnostic accuracy were significantly affected by sampling conditions, underlining the need for the implementation of standardized protocols in fecal VOC analysis.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29860824 PMCID: PMC6143285 DOI: 10.1021/acs.analchem.8b00688
Source DB: PubMed Journal: Anal Chem ISSN: 0003-2700 Impact factor: 6.986
Variables of Interest
| variables of interest | fecal sample mass (mg) | thaw–freeze cycles ( | time out of freezer (min) |
|---|---|---|---|
| reference standard | 500 | 0 | 10 |
| mass variable 1 | 300 | 0 | 10 |
| mass variable 2 | 100 | 0 | 10 |
| thaw–freeze variable 1 | 500 | 1 | 10 |
| thaw–freeze variable 2 | 500 | 2 | 10 |
| thaw–freeze variable 3 | 500 | 3 | 10 |
| 180 min out of freezer | 500 | 0 | 180 |
| storage time 1 | 500 | 0 | 10 |
| storage time 2 | 500 | 0 | 10 |
Baseline Characteristics
| inflammatory
bowel disease | ||||
|---|---|---|---|---|
| Crohn’s disease ( | ulcerative
colitis ( | healthy controls ( | ||
| sex, male ( | 10 [66.7] | 0 [0] | 14 [56] | 0.858 |
| age, yr (median [IQR]) | 13.0 [11–15] | [10–16] | 12.0 [4.0] | 0.614 |
| sample age, mos (median [IQR]) | 11.0 [2–16] | [11–26] | 11.0 [1.0] | 0.376 |
| Physician’s Global Assessment | ||||
| quiescent | 1 | 0 | ||
| mild | 9 | 2 | ||
| moderate | 5 | 0 | ||
| severe | 0 | 0 | ||
| fecal calprotectin (μg/g) (median [IQR]) | 1936 [1006–2390] | [1800–2734] | ||
| CRP (mg/L) (median [IQR]) | 24.3 [2.5–42] | 2.5 | ||
| Crohn’s
Disease Localization | ||||
| ileal (L1) | 1 | |||
| colonic (L2) | 5 | |||
| ileocolonic (L3) | 6 | |||
| proximal disease (L4) | 1 | |||
| Crohn’s
Disease Behavior | ||||
| B1 (NSNP) | 14 | |||
| B 1p (NSNP + p) | 0 | |||
| B2 (S) | 1 | |||
| B 2p (S + p) | 0 | |||
| B3 (P) | 0 | |||
| B 3p (P + p) | 1 | |||
| Ulcerative Colitis
Localization | ||||
| proctitis (E1) | 1 | |||
| left sided (E2) | 1 | |||
| extensive (E3) | 0 | |||
All values were obtained at study inclusion. Localization was obtained by ileocolonoscopy and esophagogastroduodenoscopy before treatment initiation and magnetic resonance enteroclysis. Abbreviations: IQR, interquartile range; NSNP, nonstricturing nonpenetrating; S, stricturing; P, penetrating; p, peri-anal disease.
On the basis of the Paris classification for inflammatory bowel disease (24).
Minimum-maximum values.
One missing value.
Demographics Sample Analysis of the Influence of Duration Time on VOC Profilesa
| Crohn’s
disease ( | healthy controls ( | ||
|---|---|---|---|
| sex, male ( | 5 [50] | 2 [20] | 0.350 |
| age, yr (median [IQR]) | 14.1 [3.38] | 7.8 [3.72] | 0.007 |
| sample age first measurement, mos (median [IQR]) | 23.4 [21–31] | 52.2 [51–52.4] | 0.000 |
| sample age second measurement, mos (median [IQR]) | 43.2 [41–51] | 71 [70–72] | 0.000 |
| Physician’s Global Assessment | |||
| quiescent | 0 | ||
| mild | 0 | ||
| moderate | 3 | ||
| severe | 7 | ||
| fecal calprotectin (μg/g) (median [IQR]) | 1067 [1218] | ||
| CRP (mg/L) (median [IQR]) | 29 [29] | ||
| Crohn’s
Disease Localization | |||
| ileal (L1) | 0 | ||
| colonic (L2) | 3 | ||
| ileocolonic (L3) | 7 | ||
| proximal disease (L4) | 5 | ||
| Crohn’s
Disease Behavior | |||
| B1 (NSNP) | 8 | ||
| B 1p (NSNP + p) | 0 | ||
| B2 (S) | 0 | ||
| B 2p (S + p) | 0 | ||
| B3 (P) | 1 | ||
| B 3p (P + p) | 1 | ||
All values were obtained at study inclusion. Localization was obtained by ileocolonoscopy and esophagogastroduodenoscopy before treatment initiation and magnetic resonance enteroclysis. Abbreviations: IQR, interquartile range; NSNP, nonstricturing nonpenetrating; S, stricturing; P, penetrating; p, peri-anal disease.
On the basis of the Paris classification for inflammatory bowel disease (24).
One value missing.
Performance Characteristics for the Differentiation between IBD and Healthy for All of the Variables of Interest by Fecal VOC Analysisa
| analysis | accuracy | AUC (±95% CI) | cutoff | sensitivity (±95% CI) | specificity (±95% CI) | PPV | NPV | |
|---|---|---|---|---|---|---|---|---|
| reference
standard (17 IBD, 25 HC) | 1.178 × 10–10 | 0.93 | 0.99 (0.96–1) | 0.0014 | 0.94 (0.71–1) | 0.96 (0.8–1) | 0.94 | 0.96 |
| mass variable 1 (17 IBD, 25 HC) | 0.02101 | 0.77 | 0.69 (0.52–0.86) | 0.47 | 0.88 (0.64–0.99) | 0.44 (0.24–0.65) | 0.52 | 0.85 |
| mass variable 2 (17 IBD, 25 HC) | 0.003642 | 0.70 | 0.74 (0.59–0.9) | 0.44 | 0.76 (0.5–0.93) | 0.72 (0.51–0.88) | 0.65 | 0.82 |
| thaw–freeze variable 1 (17IBD, 25HC) | 0.0004713 | 0.61 | 0.8 (0.65–0.94) | 0.49 | 0.76 (0.5–0.93) | 0.8 (0.59–0.93) | 0.72 | 0.83 |
| thaw–freeze variable 2 (17 IBD, 25 HC) | 0.7534 | 0.64 | 0.56 (0.38–0.74) | 0.66 | 0.76 (0.5–0.93) | 0.48 (0.28–0.69) | 0.5 | 0.75 |
| thaw–freeze variable 3 (17IBD, 25HC) | 0.5101 | 0.57 | 0.5 (0.32–0.69) | 0.063 | 0.47 (0.23–0.72) | 0.72 (0.51–0.88) | 0.53 | 0.67 |
| 180 min out of freezer (17 IBD, 25 HC) | 0.4596 | 0.60 | 0.51 (0.32–0.7) | 0.13 | 0.59 (0.33–0.82) | 0.68 (0.46–0.85) | 0.56 | 0.71 |
| storage duration, first measurement (10 CD vs 10 HC) | 0.0262 | 0.75 | 0.75 (0.53–0.97) | 0.47 | 0.7 (0.35–0.93) | 0.8 (0.44–0.97) | 0.78 | 0.73 |
| storage duration, second measurement (10 CD vs 10 HC) | 0.0376 | 0.75 | 0.73 (0.49–0.97) | 0.58 | 0.8 (0.44–0.97) | 0.7 (0.35–0.93) | 0.73 | 0.78 |
For each analysis, the best sparse logistic regression outcome is shown. Sensitivities, specificities, p values and AUCs are reported for the respective optimum cut points. Abbreviations: AUC, area under the curve; PPV: positive predictive value; NPV: negative predictive value.
Reference standard is defined as a 500 mg sample diluted in 10 mL of water, thawed 10 min to room temperature.
Figure 1Receiver operating characteristics for each variable of interest for the differentiation between inflammatory bowel disease and healthy states. All receiver operating characteristic curves are obtained by sparse logistic regression analyses. Abbreviations: AUC, area under the curve; IBD: Inflammatory bowel disease; HC: Healthy controls.
Figure 2Typical FAIMS pattern of patients with inflammatory bowel disease and healthy controls. Depicted with a blue background are the positive ion currents. Depicted with a red background are the negative ion currents.
Paired Feature Analyses per Variable of Interest with Corresponding p Valuesa
| variables of interest | feature 1 ( | feature 2 ( | feature 3 ( | feature 4 ( |
|---|---|---|---|---|
| Sample Mass (mg) | ||||
| 500 vs 300 | <0.0001 | <0.0001 | 0.027 | <0.0001 |
| 500 vs 100 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| Number of Freeze–Thaw Cycles | ||||
| measured directly vs one cycle | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| measured directly vs two cycles | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| measured directly vs three cycles | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| Kept at Room Temperature | ||||
| 180 minutes | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| Storage Time | ||||
| first vs second measurement | <0.0001 | <0.0001 | 0.021 | 0.825 |
p Value <0.05 is considered significant.
Figure 3Scatterplot for the differentiation between the sampling methods measured by field asymmetric ion mobility spectrometry, including the (A) sample mass; (B) number of freeze–thaw cycles; (C) 180 min out of freezer; and (D) storage duration. Axes depicted are recombinations of the raw sensor data by means of feature selection using Wilcoxon rank sum analyses, creating four features per measurement. The marked points are the individual VOC signals. The intersection of the lines derived from the individual signals are the mean VOC profile of that specific variable.